Remission could be induced and sustained in patients with early inflammatory arthritis (defined as synovitis of 12 weeks duration in at least two joints; n = 90) following 1 year of treatment with infliximab and methotrexate (MTX) in a randomized placebo-controlled trial. Patients receiving infliximab plus MTX were more likely to achieve remission at 54 weeks than patients receiving MTX alone or those receiving placebo (34% achieved remission on infliximab plus MTX versus 0% on placebo; P < 0.05). Three-quarters of patients who achieved remission on infliximab plus MTX maintained remission throughout the following year with no therapy.
References
Original article
Stamm, T. A. et al. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. Arthritis Res. Ther. 20, 174 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Intensive therapy is beneficial in early arthritis. Nat Rev Rheumatol 14, 560 (2018). https://doi.org/10.1038/s41584-018-0083-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0083-8